1 / 22

Universal Influenza Vaccine

Universal Influenza Vaccine. How To Make It Work – A State Perspective Beth Rowe-West, Head Immunization Branch Division of Public Health North Carolina DHHS Immediate Past Chair, AIM. Why We Should Expand the Recommendation. Reduction in morbidity and mortality

martha
Download Presentation

Universal Influenza Vaccine

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Universal Influenza Vaccine How To Make It Work – A State Perspective Beth Rowe-West, Head Immunization Branch Division of Public Health North Carolina DHHS Immediate Past Chair, AIM

  2. Why We Should Expand the Recommendation • Reduction in morbidity and mortality • Decrease transmission in a major reservoir – children • Potential to achieve some level of herd immunity annually • Improved ability to respond to pandemic • Lessen confusion about priority groups • Sends a message that flu is a serious health threat • Potential to expand and stabilize the flu vaccine marketplace

  3. Challenges • Public/private partnership • National, state and local • Affordability • Service delivery to all socio-economic populations • Collecting data from non-traditional health care sites • Misperceptions about Flu vaccine

  4. Ten Ingredients for Success • Stable vaccine market • Expansion of 317 funding • Support from health care providers • Effective public awareness campaign • Dispelling the myths • No thimerosal • Enhance surveillance • Influence supply driver • Phased-in approach • Effective public/private partnership

  5. 1. Stable vaccine market • Adequate supply • Practical distribution • Willingness to achieve high profit margin from increase product sales as opposed to higher cost/dose

  6. 2. Expansion of 317 program (vaccine and operations) • Relies on currently successful infrastructure of state immunization programs • Allows for streamlined service delivery • Eliminates cost as a barrier • Provides support to local agencies • Funds public awareness efforts • Supports state and local efforts

  7. 3. Support from healthcare providers • Exemplify • Educate • Promote • Vaccinate

  8. 4. Effective Public Awareness Campaign • National primetime PSAs • Statewide media coverage • Local media coverage • Multiple translations/media outlets

  9. 5. Dispel the Myths • ‘Flu vaccine causes flu’ • Duke Clinical Research Institute* : Reason for refusal for up to 48% of patients • ‘Flu vaccine not effective’ • Duke Clinical Research Institute*: Reason for refusal for 26% of patients • ‘Flu vaccine only works when given in October…November at the latest!’ • ‘I hardly ever get the flu…besides, flu is not all that serious.’ *Improving Rates of Influenza Immunization in Asthma Patients: A Duke Primary Care Research Consortium Study

  10. Top Reasons for Not Receiving Flu Vaccine Improving Rates of Influenza Immunization in Asthma Patients: A Duke Primary Care Research Consortium Study

  11. Administrative Data – Univariate Analysis of Age* • Nonlinear in both years • High in young children, decrease steadily until age 25, then increase steadily, reaching highest level at age 70 • P=0.001, logistic regression with 3 slopes • Ranges 1-26, 27-73, and 74 and older * Improving Rates of Influenza Immunization in Asthma Patients: A Duke Primary Care Research Consortium Study

  12. PERIOD 6. Eliminate Thimerosal

  13. 7. Enhanced Surveillance Using Registries • Documentation in registries essential • Second dose • Pandemic • Tracking • Mapping (learning lessons from Katrina) • Streamlined data collection • Data exchanges desirable • Aggregate data for reporting • Patient specific for billing purposes (admin fee) • Scanable devices needed for mass clinics

  14. 8. Influence Supply Driver Recommendation vs historical demand

  15. 9. Phased – in Approach • If adequate funding not immediately available, consider phased-in approach (similar to earlier hepatitis B recommendations) • Currently, high risk groups recommended • latest addition of 6-24 month olds – a potential beginning of phased-in approach • Next step: primary school age children? (grades k-5)

  16. 10. Effective Public/Private Partnerships • National: Leadership, Education • State: Coordination, Education • Local: Collaboration, Education, Vaccination

  17. National: Leadership, Education • AMA • AAP • DOE • Pharmaceutical companies • ‘up front’ vaccine purchase cost • ACIP • CMS: Creation of Vaccine for Adults Program - funding reallocation to NIP from Medicaid/Medicare to avoid • Media Outlets • Others

  18. State: Coordination, Education • Other state agencies • Regional planning teams • Support from Governor, General Assembly • Medical and nursing schools • Insurers • State AAP, AMA • Hospital Association (vaccinate at exit points for both inpatient and outpatient, grand rounds participation • Retired nurses network • Hot Line/Help Desk/Flu-finder • Media Outlets

  19. Local: Collaboration, Education and Administration • Businesses • Work site administration • Retail vaccination sites • Schools, colleges/universities • Healthcare network • Home health agencies, hospitals, SNFs • Churches • Expanded hours and weekends • Expand staff or volunteer effort during flu vaccine season • Outreach to populations without transportation • Senior Centers • Autodialers • Some mass clinics necessary • Drive through clinics • Crowd control

  20. Strategies • Multiple administration sites needed to vaccinate large number of individuals within short timeframe • Administration fees (and 3rd party reimbursement) should be significant enough to be an incentive for the private sector, whether a health care provider or non-traditional sites (eg, retail shopping) • Duplication of school-site initiatives to increase coverage among school age children • Worksites initiatives • Phased-in approach

  21. Where Do We Go From Here? • Consider phased in approach over the next 3-5 years, beginning with school age children. This should help: • Jump start a decline in flu morbidity and mortality • Stabilize vaccine market • Enhance immunization program infrastructure Meanwhile… • Encourage pharmaceutical companies to eliminate thimerosal from flu vaccine • Significantly reduce highly prevalent patient misconceptions about flu vaccine. • Significantly increase flu vaccine coverage rates among healthcare workers. • Educate the public about the necessity of flu vaccine. • Develop VFA program • Plan for expansion

  22. Questions?

More Related